Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
| Autor: | Sorli, Christopher, Harashima, Shin-ichi, Tsoukas, George M, Unger, Jeffrey, Karsbøl, Julie Derving, Hansen, Thomas, Bain, Stephen C |
|---|---|
| Zdroj: | In The Lancet Diabetes & Endocrinology April 2017 5(4):251-260 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|